Sandbox: differentialdx maria: Difference between revisions
No edit summary |
No edit summary |
||
Line 1: | Line 1: | ||
{|style="border: 5px; font-size: 90%; margin: 5px; width: 1000px" align=center | |||
!style="padding: 5px 5px; background: #4479BA; font-weight: bold; text-align:center;" colspan="2"|{{fontcolor|#FFF|'''Genetic lesions and potential therapeutic drugs'''<br><SMALL> Adapted from Chiaretti et al</SMALL>}} | |||
|valign=top| | |||
|+ | |||
|- | |||
!style="background: #4479BA; width: 300px; text-align:center;" | {{fontcolor|#FFF|'''Genes involved'''}} | |||
!style="background: #4479BA; width: 300px; text-align:center;" | {{fontcolor|#FFF|'''Therapeutic compound'''}} | |||
|- | |||
| style="padding: 5px 5px; background: #DCDCDC; font-weight: bold; text-align:center;"| TAL1 | |||
| style="padding: 5px 5px; background: #F5F5F5;"| HDAC inhibitors | |||
|- | |||
|style="padding: 5px 5px; background: #DCDCDC; font-weight: bold; text-align:center;"| Notch1 | |||
|style="padding: 5px 5px; background: #F5F5F5;"| Y-secretase inhibitors | |||
|- | |||
| style="padding: 5px 5px; background: #DCDCDC; font-weight: bold; text-align:center;"| ABL1 | |||
| style="padding: 5px 5px; background: #F5F5F5;"| ABL1 kinase inhibitors | |||
|- | |||
| style="padding: 5px 5px; background: #DCDCDC; font-weight: bold; text-align:center;"| JAK2 | |||
| style="padding: 5px 5px; background: #F5F5F5;"| JAK2 inhibitors | |||
|- | |||
| style="padding: 5px 5px; background: #DCDCDC; font-weight: bold; text-align:center;"| JAK1 | |||
| style="padding: 5px 5px; background: #F5F5F5;"| Tyrosine kinase inhibitors | |||
|} | |||
{|style="border: 5px; font-size: 90%; margin: 5px; width: 800px" align=center | {|style="border: 5px; font-size: 90%; margin: 5px; width: 800px" align=center | ||
!style="padding: 5px 5px; background: #4479BA; font-weight: bold; text-align:center;" colspan="2"|{{fontcolor|#FFF|'''WHO histological classification<br>Tumors of the appendix <br><SMALL> Adapted from WHO/IARC </SMALL>'''}} | !style="padding: 5px 5px; background: #4479BA; font-weight: bold; text-align:center;" colspan="2"|{{fontcolor|#FFF|'''WHO histological classification<br>Tumors of the appendix <br><SMALL> Adapted from WHO/IARC </SMALL>'''}} |
Latest revision as of 15:53, 27 April 2016
Genetic lesions and potential therapeutic drugs Adapted from Chiaretti et al |
||
---|---|---|
Genes involved | Therapeutic compound | |
TAL1 | HDAC inhibitors | |
Notch1 | Y-secretase inhibitors | |
ABL1 | ABL1 kinase inhibitors | |
JAK2 | JAK2 inhibitors | |
JAK1 | Tyrosine kinase inhibitors |
WHO histological classification Tumors of the appendix Adapted from WHO/IARC |
||
---|---|---|
Epithelial tumors | ||
| ||
Non-epithelial tumors | ||
| ||
Secondary tumors | ||
| ||
Hyperplastic polyp |
CIN is classified in grades:
Histology Grade | Description | Image |
---|---|---|
– | Normal cervical epithelium | |
CIN 1 (Grade I) | The least risky type, represents only mild dysplasia, or abnormal cell growth.It is confined to the basal 1/3 of the epithelium. This corresponds to infection with HPV, and typically will be cleared by immune response in a year or so, though can take several years to clear. | |
CIN 2/3 | Formerly subdivided into CIN2 and CIN3. | |
CIN 2 (Grade II) | Moderate dysplasia confined to the basal 2/3 of the epithelium | |
CIN 3 (Grade III) | Severe dysplasia that spans more than 2/3 of the epithelium, and may involve the full thickness. This lesion may sometimes also be referred to as cervical carcinoma in situ. |
Ultrasound findings of common liver masses | ||
---|---|---|
Common liver masses | Ultrasound finding | |
Hepatic hemangioma |
| |
Focal nodular hyperplasia |
| |
Hepatic adenoma |
| |
Idiopathic noncirrhotic portal hypertension |
| |
Hepatocellular carcinoma |
| |
Cholangiocarcinoma |
| |
Metastases |
|
Classification of liver mass | ||
---|---|---|
Benign | Malignant | |
|
|
Cavitating causes | Conditions | Description |
---|---|---|
Malignancy |
Cancer
|
Cancer
|
Infection |
|
Abscess:
Empyema:
|
Non-infectious |
|
|
Vascular |
|
|
Trauma |
|
|
Congenital |
|
|
Imaging features of lung mass | ||
---|---|---|
Hyperdense pulmonary mass | Cavitating pulmonary mass | |
|
Cancer
Autoimmune
Vascular
Infections (bacterial/fungal)
Trauma
Youth
|
Classification of Benign and Malignant Pulmonary Mass | |||
---|---|---|---|
Lung mass (location) | Benign | Malignant | |
Endobronchial |
|
| |
Parenchymal |
|
| |
Pleural |
|
|
Radiologic Features Suggestive of Benign or Malignant Solitary Pulmonary Nodules Adapted from American Academy of Family Physicians [1] |
|||
---|---|---|---|
Radiologic feature | Benign | Malignant | |
Size | < 5 mm | > 10 mm | |
Border | Smooth | Irregular or spiculated | |
Density | Dense, solid | Nonsolid, “ground glass” | |
Calcification | Typically a benign feature, especially in “concentric,” “central,” “popcorn-like,” or “homogeneous” patterns | Typically noncalcified, or “eccentric” calcification | |
Doubling time | Less than one month; more than one year | One month to one year |
Recommendations for Follow-up and Management of Nodules <8 mm Detected Incidentally at Non-screening CT
Nodule Size (mm) | Low risk patients | High risk patients |
---|---|---|
Less than or equal to 4 | |No follow-up needed. | Follow-up at 12 months. If no change, no further imaging needed. |
>4 - 6 | Follow-up at 12 months. If no change, no further imaging needed. | Initial follow-up CT at 6 -12 months and then at 18 - 24 months if no change. |
>6 - 8 | Initial follow-up CT at 6 -12 months and then at 18 - 24 months if no change. | Initial follow-up CT at 3 - 6 months and then at 9 -12 and 24 months if no change. |
> 8 | Follow-up CTs at around 3, 9, and 24 months. Dynamic contrast enhanced CT, PET, and/or biopsy | Same at for low risk patients |
Note: Newly detected indeterminate nodule in persons 35 years of age or older.[2]
- Low risk patients: Minimal or absent history of smoking and of other known risk factors.
- High risk patients: History of smoking or of other known risk factors.
Differential Diagnosis for Solitary Pulmonary Adapted from Erasmus et al. [1] |
||
---|---|---|
Differential Diagnosis | Causes | |
Malignant neoplasms |
| |
Benign neoplasms |
| |
Infectious inflammatory |
| |
Non-infectious inflammatory |
| |
Vascular |
| |
Congenital |
| |
Miscellaneous |
|
Differential Diagnosis | Similar Features | Differentiating Features |
---|---|---|
Pulmonary tuberculosis |
|
|
Lung abscess |
|
|
Pneumonia |
|
|
Pulmonary fungal infection |
|
|
Other non-small cell lung cancers (adenocarcinoma and squamous cell lung cancer) |
|
|
Differential Diagnosis | Similar Features | Differentiating Features |
---|---|---|
Pulmonary tuberculosis |
|
|
Sarcoidosis |
|
|
Pneumonia |
|
|
Pulmonary fungal infection |
|
|
Metastases |
|
|
Stage (TNM criteria) | Standard Treatment Options |
---|---|
Occult |
|
Stage 0 |
|
Stages IA and IB |
|
Stages IIA and IIB |
|
Stage IIIA |
Resected or resectable disease
Unresectable disease
Superior sulcus tumors
Tumors that invade the chest wall
|
Stage IIIB |
|
Stage IV |
Maintenance therapy following first-line chemotherapy
|
Recurrent |
|
Type of tumor | Biopsy findings |
---|---|
Lung adenocarcinoma |
|
Squamous cell lung carcinoma |
|
Large cell lung carcinoma |
|
Adenosquamous carcinoma |
|
Sarcomatoid carcinoma |
|
Carcinoid tumor |
|
Salivary gland tumor |
|
Organization Screening Guidelines for Non Small Cell Lung Cancer Adapted from CDC (2016) [1] |
|||
---|---|---|---|
Organization | Groups eligible for screening | Year | |
American Academy of Family Practice | Evidence is insufficient to recommend for or against screening | 2013 | |
American Association of Thoracic Surgery |
1. Age 55 to 79 years with 30 pack year smoking history. 2. Long term lung cancer survivors who have completed 4 years of surveillance without recurrence and who can tolerate lung cancer treatment following screening to detect second primary lung cancer until the age of 79. 3. Age 50 to 79 years with a 20 pack year smoking history and additional comorbidity that produces a cumulative risk of developing lung cancer ≥ 5% in 5 years |
2012 | |
American Cancer Society |
Age 55 to 74 years with ≥30 pack year smoking history, who either currently smoke or have quit within the past 15 years, and who are in relatively good health. |
2015 | |
American College of Chest Physicans |
Age 55 to 74 years with ≥30 pack year smoking history,who either currently smoke or have quit within the past 15 years |
2013 | |
American Society of Clinical Oncology |
Age 55 to 74 years with ≥30 pack year smoking history,who either currently smoke or have quit within the past 15 years |
2012 | |
American Lung Association |
Age 55 to 74 years with ≥ 30 pack year smoking history and no history of lung cancer |
2012 | |
Medicaid Services |
Age 55 to 77 years with ≥ 30 pack year smoking history and smoking cessation < 15 years |
2015 | |
National Comprehensive Cancer Network |
Age 55 to74 years with ≥30 packyear smoking history and smoking cessation < 15 years OR Age ≥ 50 years and ≥20 pack year smoking history and additional risk factor (other than secondhand smoke exposure |
2015 | |
U.S Preventive Services Task Force |
Age 55 to 80 years with ≥30 pack year smoking history and smoking cessation < 15 years. |
2013 |
Procedure | Advantages | Disadvantages |
---|---|---|
Thoracotomy (surgical opening of the chest) | Allows the most thorough inspection and sampling of lymph node stations, may be followed by resection of tumor, if feasible | Most invasive approach, not indicated for staging alone, significant risk of procedure-related morbidity |
Left parasternal mediastinotomy (or anterior mediastinotomy) | Permits evaluation of the aortopulmonary window lymph nodes | More invasive; false-negative rate approximately 10%. |
Chamberlain procedure | Access to station 5 (aortopulmonary window lymph node) | Limited applications, invasive |
Cervical mediastinoscopy | Still considered the gold standard (usual comparitor) by many, excellent for 2RL 4RL | Does not cover all medastinal lymph node stations, particularly subcarinal lymph nodes (station 7), paraesophageal and pulmonary ligament lymph nodes (stations 8 and 9), the aortopulmonary window lymph nodes (station 5), and the anterior mediastinal lymph nodes (station 6); false-negative rate approximately 20%; invasive |
Video-assisted thoracoscopy | Good for inferior mediastinum, station 5 and 6 lymph nodes | Invasive, does not cover superior anterior mediastinum |
Transthoracic percutaneous fine needle aspiration (FNA) under CT guidance | More widely available than some other methods | Traverses a lot of lung tissue, therefore high pneumothorax risk, some lymph node stations inaccessible |
Bronchoscopy with blind transbronchial FNA (Wang needle) | Less invasive than above methods | Relatively low yield, not widely practiced, bleeding risk |
Procedure | Advantages
style="padding: 5px 5px; background: #F5F5F5;"| | |
---|---|---|
Endobronchial ultrasound (EBUS) |
|
|
Endoscopic ultrasound (EUS) |
|
|
Differential Diagnosis | Similar Features | Differentiating Features |
---|---|---|
Pulmonary tuberculosis | Chronic cough, weight loss, hemoptysis, nocturnal diaphoresis, dyspnea | In pulmonary tuberculosis, differentiating features include: increase in diameter despite optimal medical therapy, patients age is usually younger, hemoptisis is an early feature, and CXR anatomical predilection for upper lobes |
Lung abscess | Chronic cough, weight loss, hemoptysis, and dyspnea | In lung abscess, differentiating features include: acute or subacute onset, CXR anatomical predilection for upper lobes, and usually resolve with antibiotic |
Pneumonia | Chronic cough, weight loss, hemoptysis, and dyspnea | In pneumonia, differentiating features include: good response to antibiotics, acute onset, predilection on CXR is consolidation, laboratory markers indicate infection. |
Fungal infection | Chronic cough, weight loss, hemoptysis, and dyspnea | In fungal infection, differentiating features include: CXR findings: air-cresecent sign, no response to antibioitcs, and mimcs tuberculosis. |
Chronic eosinophilic pneumonia | Chronic cough, weight loss, hemoptysis, and dyspnea | In chronic eosinophilic pneumonia , differentiating features include: followed by a parasite infection or medication exposure, and increased serum IgE levels |
Age-adjusted incidence of lung cancer by histological type Adapted from Wikipedia [3] |
|||
---|---|---|---|
All types | 66.9 | ||
Adenocarcinoma | 22.1 | ||
Squamous-cell carcinoma | 14.4 |
Age-adjusted incidence of lung cancer by histological type Adapted from Wikipedia [3] |
|||
---|---|---|---|
Type | Incidence per 100,000 per year | ||
All types |
66.9 | ||
Adenocarcinoma |
22.1 | ||
Squamous-cell carcinoma |
14.4 |
Classification: Mucoepidermoid Carcinomas Adapted from Radiopedia [4] |
|||
---|---|---|---|
Salivary gland-confined carcinomas |
|
| |
|
| ||
Other organ mucoepidermoid carcinomas |
|
WHO histological classification system Adapted from WHO/IARC (2006) [4] |
|||
---|---|---|---|
Main types | Subtypes | Prevalence | |
Adenocarcinoma |
|
| |
Squamous cell carcinoma |
|
| |
Large cell carcinoma |
|
| |
Less common types | |||
Adenosquamous carcinoma |
|
| |
Sarcomatoid carcinoma |
|
| |
Carcinoid tumor |
|
| |
Salivary gland tumor |
|
|
Genes | Presence in non small cell-lung cancers |
---|---|
EGFR |
|
KRAS |
|
ALK |
|
HER2 |
|
BRAF |
|
ROS-1 |
|
Classification | ||
---|---|---|
Salivary gland-confined carcinomas |
|
|
|
| |
Other organ mucoepidermoid carcinomas |
|
Mucoepidermoid carcinoma staging | |
---|---|
Tumor |
|
| |
| |
| |
| |
Nodes |
|
| |
| |
| |
| |
Overall stage |
|
| |
| |
| |
| |
|
Differential Diagnosis | Similar Features | Differentiating Features |
---|---|---|
Benign mixed tumor | Painless parotid swelling and facial deformity | In benign mixed tumor , differentiating features include: histopathological findings |
Warthin tumor | Painless swelling and facial deformity | In warthin tumor differentiating features include: multicentric presentation (20%) and are usually small (1-4 cm), highly associated with smoking |
Adenoid cystic carcinoma | Swelling on salivary gland and facial deformity | In adenoid cystic carcinoma, differentiating features include: tendency for perineural extension, distribution, and mainly occur in relation to the airways |
Metastasis | Painless swelling and facial deformity | In metastasis, differentiating features include: primary tumor origin, and histopathological findings. |
Type of tumor | Age | Location | Histological features | Imaging features | Origin | Bone/Cartilage |
---|---|---|---|---|---|---|
Osteoma | 40-50 years | Skull bones | Matured lamellar bone | Sclerotic | Benign | Bone |
Osteoid osteoma | 10-20 years | Short and long bone diaphysis | Osteiod outlined by osteoblasts, incorporated in a fibrous stroma | Sclerotic | Benign | Bone |
Osteosarcoma | 11-40 years | Long bones metaphysis | Osteoid and bone formed of malignant osteoblasts and fibroblasts | Sclerotic | Malignant | Bone |
Chondroma | 30-60 years | Small tubular bones of the hands and feet | Maturated hyaline cartilage (enchondroma/ecchondroma), preserving lobulation | Well-defined | Malignant | Cartilage |
Chondrosarcoma | 30-60 years | Long bones metaphysic, axial skeleton | Immature cartilage, no preserving lobulation, cells arranged in groups of two or four, with atypia and mitosis | Well-defined | Malignant | Cartilage |
Ewing sarcoma | 5-25 years | Long bones diaphysis | Small, round, undifferentiated cells, no stroma, a lot of capillary arrangement. | Ill-defined | Malignant | Bone |
Giant cell tumor | 20-40 years | Knee | Multinucleated giant cells, fusiform cells, mononuclear cells. | Well-defined | Malignant | Bone |
Metastases | 50-90 years | No site predilection | Frequently adenocarcinomas. Metastases can be blastic or lytic depending on the tumor origin | Sclerotic | Malignant | Bone |
Stage | Description |
---|---|
I |
|
II |
|
III |
|
Differential Diagnosis | Similar Features | Differentiating Features |
---|---|---|
Enchondroma |
|
|
Chondroblastoma |
|
|
Periosteal chondroma |
|
|
Chondromyxoid fibroma |
|
|
Type of osteochondroma | Features |
---|---|
Solitary osteochondroma |
|
Multiple osteochondromas (hereditary) |
|
Genes implicated in HNPCC | Frequency of mutations in HNPCC families | Locus |
---|---|---|
MSH2 | approximately 60% | 2p22 |
MLH1 | approximately 30% | 3p21 |
MSH6 | 7-10% | 2p16 |
PMS2 | relatively infrequent | 7p22 |
PMS1 | case report | 2q31-q33 |
TGFBR2 | case report | 3p22 |
MLH3 | disputed | 14q24.3 |
Type of osteoid osteoma | Characteristics |
---|---|
Intracortical | Dense sclerosis around the nidus |
Periosteal | Periosteal reaction |
Cancellous (medullary) | Produces very little reactive bone |
Subarticular | Simulates arthritis as it produces synovial reactions |
Differential Diagnosis | Similar Features | Differentiating Features |
---|---|---|
Osteoblastoma |
|
|
Brodie abscess |
|
|
Osteosarcoma |
|
|
Enostosis |
|
|
Differential Diagnosis | Similar Features | Differentiating Features |
---|---|---|
Fibrous dysplasia |
|
|
Osteoblastoma |
|
|
Adamantinomas |
|
|
Chronic sinusitis |
|
|
Differential Diagnosis | Similar Features | Differentiating Features |
---|---|---|
Cardiac tamponade |
|
|
Chronic obstructive pulmonary disease |
|
|
Mediastinitis |
|
|
Pneumonia |
|
|
Acute respiratory distress syndrome |
|
|
Syphilis |
|
|
Differential Diagnosis | Similar Features | Differentiating Features |
---|---|---|
Familial adenomatous polyposis (FAP) |
|
|
Juvenile polyposis |
|
|
Cowden syndrome |
|
|
- ↑ 1.0 1.1 1.2 Solitary Pulmonary Nodule: Morphological Evaluation. http://pubs.rsna.org/doi/pdf/10.1148/radiographics.20.1.g00ja0343 Accessed on March 15, 2016
- ↑ Heber MacMahon, John H. M. Austin, Gordon Gamsu, Christian J. Herold, James R. Jett, David P. Naidich, Edward F. Patz, Jr, and Stephen J. Swensen. Guidelines for Management of Small Pulmonary Nodules Detected on CT Scans: A Statement from the Fleischner Society. Radiology 2005 237: 395-400.
- ↑ 3.0 3.1 Lung Cancer Epidemiology. Wikipedia. https://en.wikipedia.org/wiki/Lung_cancer Accessed on February 17, 2016
- ↑ 4.0 4.1 4.2 Mucoepidermoid carcinoma. Radiopedia. Dr Frank Gailliard. http://radiopaedia.org/articles/mucoepidermoid-carcinoma-of-salivary-glands Accessed on February 17, 2016
- ↑ AJCC System for Staging of Benign and Malignant Salivary Gland Tumors. AJCC Accessed on February 18, 2016